| 7.76 0.07 (0.91%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.27 | 1-year : | 12 |
| Resists | First : | 8.8 | Second : | 10.27 |
| Pivot price | 7.77  |
|||
| Supports | First : | 7.22 | Second : | 6.25 |
| MAs | MA(5) : | 8.05 |
MA(20) : | 7.49 |
| MA(100) : | 5.7 |
MA(250) : | 4.11 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 59.2 |
D(3) : | 68.8 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 8.8 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TNGX ] has closed above bottom band by 49.4%. Bollinger Bands are 11.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.95 - 8 | 8 - 8.05 |
| Low: | 7.62 - 7.69 | 7.69 - 7.75 |
| Close: | 7.66 - 7.76 | 7.76 - 7.86 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Wed, 17 Sep 2025
Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected - simplywall.st
Wed, 17 Sep 2025
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Tue, 26 Aug 2025
Leading Biotech Tango Therapeutics CEO Barbara Weber to Share Company Updates at 2025 Cantor Conference - Stock Titan
Tue, 05 Aug 2025
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Tue, 05 Aug 2025
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Fri, 06 Jun 2025
TNGX Stock Price and Chart — NASDAQ:TNGX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 111 (M) |
| Held by Insiders | 3.238e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 25,160 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.548e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 287.8 % |
| Return on Equity (ttm) | -31.8 % |
| Qtrly Rev. Growth | 2.43e+007 % |
| Gross Profit (p.s.) | -50 |
| Sales Per Share | -45.3 |
| EBITDA (p.s.) | -6.6756e+007 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.18 |
| Price to Cash Flow | 10.68 |
| Dividend | 0 |
| Forward Dividend | 2.68e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|